CORT

Corcept Therapeutics Incorporated
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$9.98B
P/E Ratio
273.35
EPS
$0.34
Beta
0.46
52W High
$94.77
52W Low
$28.66
50-Day MA
$69.16
200-Day MA
$60.85
Dividend Yield
Profit Margin
6.16%
Forward P/E
111.11
PEG Ratio
0.81

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$769.10M
Gross Profit (TTM)$755.64M
EBITDA$-6.93M
Operating Margin-30.10%
Return on Equity7.17%
Return on Assets-0.62%
Revenue/Share (TTM)$7.40
Book Value$5.94
Price-to-Book15.18
Price-to-Sales (TTM)12.97
EV/Revenue12.16
EV/EBITDA99.13
Quarterly Earnings Growth (YoY)-21.60%
Quarterly Revenue Growth (YoY)4.90%
Shares Outstanding$107.35M
Float$89.94M
% Insiders11.54%
% Institutions75.56%

Historical Volatility

HV 10-Day
25.96%
HV 20-Day
36.82%
HV 30-Day
41.87%
HV 60-Day
47.15%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($88.00 target)
1
Strong Buy
4
Buy
1
Hold

Latest News

Why Crinetics Stock Soared 99% This Week

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

24/7 Wall Street7/9/2026Positive
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

New York, New York--(Newsfile Corp. - June 16, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.

Newsfile Corp6/17/2026Neutral
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (Ame.

Business Wire5/29/2026Neutral
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. “Following issuan.

Business Wire5/27/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026